On Oct 31, major Wall Street analysts update their ratings for $IDEX Corp (IEX.US)$, with price targets ranging from $230 to $248.
TD Cowen analyst Joseph C Giordano maintains with a buy rating, and maintains the target price at $230.
Baird analyst Michael Halloran maintains with a buy rating, and maintains the target price at $241.
Oppenheimer analyst Bryan Blair maintains with a buy rating, and maintains the target price at $238.
RBC Capital analyst Deane Dray maintains with a buy rating, and adjusts the target price from $236 to $248.
Furthermore, according to the comprehensive report, the opinions of $IDEX Corp (IEX.US)$'s main analysts recently are as follows:
Following Idex Corp.'s third-quarter earnings surpassing expectations, the company's modest 1% operating income beat and improved 2024 guidance forecasts were noted. However, the key factor contributing to the stock's 7% relief rally was the reported stabilization in the life sciences area within the Health & Science Technologies segment after a lengthy phase of destocking and underperformance.
The firm noted that Idex Corp.'s 3Q results were operationally aligned, with upside from FSDP counterbalancing downside in FMT. The company's 2024 guidance improved at the lower end, and the 4Q outlook aligns with consensus. Additionally, signs of stabilization are emerging, as indicated by daily order rates, demand commentary, and estimates, which is a positive development after a challenging time for the company.
Here are the latest investment ratings and price targets for $IDEX Corp (IEX.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月31日，多家华尔街大行更新了$IDEX Corp (IEX.US)$的评级，目标价介于230美元至248美元。
TD Cowen分析师Joseph C Giordano维持买入评级，维持目标价230美元。
贝雅分析师Michael Halloran维持买入评级，维持目标价241美元。
奥本海默控股分析师Bryan Blair维持买入评级，维持目标价238美元。
加皇资本市场分析师Deane Dray维持买入评级，并将目标价从236美元上调至248美元。
此外，综合报道，$IDEX Corp (IEX.US)$近期主要分析师观点如下：
在idex corp第三季度收益超出预期之后，该公司谨慎的1%营业利润增幅以及改善的2024年指导预测受到关注。然而，股票上涨7%的主要因素是报告称，在经历了长时间的去库存和表现不佳后，健康与科学技术领域内的生命科学领域稳定下来。
公司指出，Idex Corp的第三季度结果在运营上得到了配合，FSDP方面的上涨抵消了FMt方面的下降。公司的2024年指导在较低端实现改喀，第四季度的展望与共识相符。此外，迹象表明，每日订单率、需求评论和估算正在出现稳定的迹象，这是在公司经历了一段艰难时期之后的积极发展。
以下为今日4位分析师对$IDEX Corp (IEX.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
